Biosortia Pharmaceuticals is the only company in the world directly accessing the aquatic
microbiome for metabolite and elicited secondary metabolite chemistry from unculturable and
culturable microorganisms. Biosortia typically samples and processes >20,000,000 liters of
dilute microbial consortia (.02g/l) with no environmental impact. These proprietary
technologies and processes permit direct chemical access of highly refined mixtures of chemistry
for the screening of high priority unmet needs in key therapeutic areas. Biosortia has proven
access and continued accessibility to previously unobtainable active, potent and novel chemistry,
virtually eliminating key historical hurdle issues with aquatic drug discovery.